RDY

Business Context and Reporting Period

Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter and Nine Months ended December 31, 2009
Currency: Indian Rupees (Rs.) with U.S. Dollar (U.S.$) convenience translation (Rate: Rs. 46.40 = U.S.$1.00)
Business Overview: DRL is a leading India-based pharmaceutical company operating in Pharmaceutical Services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. Principal operations are in India, with significant marketing and manufacturing presence in the U.S., Europe (notably Germany), Russia, and other emerging markets.

Key Financial Metrics

Revenue (Nine Months Ended Dec 31, 2009): Rs. 53,854 million (U.S.$ 1,161 million), an increase of 8.6% compared to Rs. 49,590 million in the prior year period.
Net Profit/Loss (Nine Months Ended Dec 31, 2009): Net loss of Rs. 597 million (U.S.$ 13 million), compared to a net profit of Rs. 4,609 million in the prior year period.
Net Profit/Loss (Three Months Ended Dec 31, 2009): Net loss of Rs. 5,217 million (U.S.$ 112 million), compared to a net profit of Rs. 2,445 million in the prior year period.
Gross Margin: 51.4% for the nine months ended Dec 31, 2009 (down from 51.9% in the prior year).
Operating Cash Flow (Nine Months): Net cash inflow of Rs. 11,422 million (U.S.$ 246 million), a significant improvement from an outflow of Rs. 678 million in the prior year.
Debt and Liquidity:

• Cash and Cash Equivalents: Rs. 5,539 million (U.S.$ 119 million) as of Dec 31, 2009.
• Total Borrowings: Short-term borrowings of Rs. 1,520 million and Long-term borrowings of Rs. 6,971 million (non-current) plus Rs. 4,026 million (current portion).
• Undrawn Credit Lines: Rs. 12,751 million available for working capital.

Material Changes vs. Prior Period

The financial results for the period were materially impacted by significant non-recurring impairment charges related to the German subsidiary, betapharm Arzneimittel GmbH ("betapharm").

• Impairment Charges: The Company recorded an impairment loss on goodwill of Rs. 5,147 million and an impairment loss on other intangible assets of Rs. 3,456 million during the quarter ended December 31, 2009. These charges were driven by adverse market conditions in Germany, specifically the shift to a tender-based pricing model by State Healthcare Insurance funds, which reduced forecasted sales and profitability.
• Revenue Trends: While total revenue grew 8.6% year-over-year for the nine-month period, the Global Generics segment saw a decline in the quarter (down 14% vs. prior year) primarily due to the absence of sumatriptan sales (which launched in late 2008) and the German market challenges. Excluding sumatriptan, underlying revenue growth was positive.
• Segment Performance:
  • PSAI: Revenue increased 11% (nine months) driven by growth in Europe, India, and Rest of World.
  • Global Generics: Revenue increased 6.7% (nine months) but faced headwinds in North America (excluding sumatriptan) and Germany.
  • Proprietary Products: Revenue increased significantly (138% for nine months) but remains a small portion of total revenue.
• Inventory Write-downs: Increased to Rs. 857 million for the nine months ended Dec 31, 2009, largely due to expiring inventory in German operations and sumatriptan genericization.

Guidance, Outlook, and Risks

Outlook and Guidance:

• Management revised its full-year revenue growth projection for the fiscal year ending March 31, 2010, down from an earlier projection of 10% to a "lower, single digit growth" compared to the prior fiscal year.
• Despite lower revenue growth, the Company expects to meet its Return on Capital Employed (ROCE) projections for the full year, adjusted for non-recurring charges.
• Germany: The market remains challenging with a shift to "high volumes and low margins." The Company is implementing workforce reductions and cost rationalization to mitigate profitability erosion.
• North America: A voluntary recall of four products in September 2009 caused a temporary slowdown in production and revenue. The Company has addressed FDA observations and expects to recover.
• India & Russia: These markets continue to be key growth drivers, with India showing 18% revenue growth and Russia showing 28% growth for the nine-month period.

Risks and Contingencies:

• Patent Litigation: Ongoing litigation regarding Fexofenadine (U.S.), Alendronate Sodium (Germany), and Olanzapine (Canada). The Company believes these will not have a materially adverse effect but acknowledges potential damages if unsuccessful.
• Regulatory Matters: Investigations by U.S. Attorneys General regarding marketing practices of certain products (ranitidine, fluoxetine, buspirone) sold through a partner.
• Environmental: Pending litigation regarding environmental compensation in India, though the Company believes additional liability is remote.
• Subsequent Events: Post-December 31, 2009, the Company agreed to further workforce reductions in Germany with an estimated termination benefit cost of Rs. 450 million.

Key Facts for Investor Verification

• Impairment Impact: Verify the sustainability of the German business model post-impairment and the accuracy of the revised revenue forecasts for the betapharm subsidiary.
• North America Recall: Confirm the resolution of the FDA observations and the extent of customer diversion caused by the September 2009 product recall.
• Litigation Exposure: Monitor the status of the Fexofenadine and Olanzapine patent litigations, as adverse rulings could result in significant damages or market exclusions.
• Cash Flow vs. Net Income: Note the divergence between the reported net loss (due to non-cash impairments) and the strong positive operating cash flow of Rs. 11,422 million.
• Debt Repayment: Review the Company's strategy for debt reduction, as financing activities resulted in a net cash outflow of Rs. 8,306 million primarily due to loan repayments and dividends.